Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL

被引：0

作者：

Porter, David L. ^{[1
]}

Frey, Noelle V. ^{[2
]}

Melenhorst, J. Joseph ^{[3
]}

Hwang, Wei-Ting ^{[4
]}

Lacey, Simon F. ^{[1
]}

Shaw, Pamela ^{[5
]}

Chew, Anne ^{[5
]}

Grupp, Stephan A. ^{[1
,6
]}

Capobianchi, James ^{[5
]}

Gilmore, Joan ^{[1
]}

Kalos, Michael

Litchman, Manuel ^{[4
,7
]}

Lledo, Lester ^{[1
]}

Loren, Alison Wakoff ^{[1
]}

Mahnke, Yolanda ^{[1
]}

Marcucci, Katherine T. ^{[1
]}

McConville, Holly ^{[1
]}

Shen, Angela ^{[8
]}

Wood, Patricia A. ^{[8
]}

Zheng, Zhaohui ^{[1
]}

Levine, Bruce L. ^{[5
]}

June, Carl H. ^{[5
]}

机构：

[1] Univ Penn, Philadelphia, PA 19104 USA

[2] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[3] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[4] Univ Penn, Sch Med, Philadelphia, PA 19104 USA

[5] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA

[6] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA

[7] Novartis, E Hanover, NJ USA

[8] Novartis Pharmaceut, E Hanover, NJ USA

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[21] T CELLS ENGINEERED WITH A CHIMERIC ANTIGEN RECEPTOR (CAR) TARGETING CD19 (CTL019 CELLS) PRODUCE SIGNIFICANT IN VIVO PROLIFERATION, COMPLETE RESPONSES AND LONG-TERM PERSISTENCE WITHOUT GVHD IN CHILDREN AND ADULTS WITH RELAPSED, REFRACTORY ALL
Grupp, S.
Frey, N.
Aplenc, R.
Levine, B.
Maude, S.
Rheingold, S.
Barker, C. Strait
Teachey, D.
Mahnke, Y.
Porter, D.
June, C.
BONE MARROW TRANSPLANTATION, 2014, 49 : S1 - S1
[22] T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL
Grupp, Stephan A.
Frey, Noelle V.
Aplenc, Richard
Barrett, David M.
Chew, Anne
Kalos, Michael
Levine, Bruce L.
Litchman, Manuel
Maude, Shannon L.
Rheingold, Susan R.
Shen, Angela
Strait, Christine
Teachey, David T.
Wood, Patricia A.
Porter, David
June, Carl H.
BLOOD, 2013, 122 (21)
[23] DURABLE REMISSIONS WITH CONTROL OF CYTOKINE RELEASE SYNDROME (CRS) USING T CELLS EXPRESSING CD19 TARGETED CHIMERIC ANTIGEN RECEPTOR (CAR) CTL019 TO TREAT RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOID LEUKEMIA (ALL)
Levine, B. L.
Maude, S.
Zheng, Z.
Shaw, P.
Ambrose, D.
Aplenc, R.
Barker, C.
Barrett, D.
Brogdon, J.
Callahan, C.
Chen, F.
Chew, A.
Davis, M. M. Suhoski
Fesnak, A. D.
Finklestein, J.
Frey, N.
Lacey, S.
Lamontagne, A.
Lewitt, L.
Loew, A.
Marcucci, K.
Melenhorst, J.
Motley, L.
Mudambi, M.
Nazimuddin, F.
O'Rourke, M.
Porter, D.
Rheingold, S. R.
Scholler, J.
Tayor, C.
White, C.
Wood, P.
Young, R.
Teachey, D. T.
June, C.
Grupp, S.
CYTOTHERAPY, 2016, 18 (06) : S14 - S15
[24] Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL
Maude, Shannon L.
Barrett, David M.
Ambrose, David E.
Rheingold, Susan R.
Aplenc, Richard
Teachey, David T.
Callahan, Colleen
Barker, Christine S.
Mudambi, Maya
Shaw, Pamela A.
Brogdon, Jennifer
Young, Regina M.
Scholler, John
Loew, Andreas
Marcucci, Katherine T.
Finklestein, Jeffrey
Kulikovskaya, Irina
Nazimuddin, Farzana
Zheng, Zhaohui
Levine, Bruce L.
Porter, David L.
Lacey, Simon F.
Melenhorst, Jan J.
June, Carl H.
Grupp, Stephan A.
BLOOD, 2015, 126 (23)
[25] Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
Garfall, Alfred L.
Maus, Marcela V.
Hwang, Wei-Ting
Lacey, Simon F.
Mahnke, Yolanda D.
Melenhorst, J. Joseph
Zheng, Zhaohui
Vogl, Dan T.
Cohen, Adam D.
Weiss, Brendan M.
Dengel, Karen
Kerr, Naseem D. S.
Bagg, Adam
Levine, Bruce L.
June, Carl H.
Stadtmauer, Edward A.
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (11): : 1040 - 1047
[26] Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
Guoqing Wei
Lijuan Ding
Jiasheng Wang
Yongxian Hu
He Huang
Experimental Hematology & Oncology, 6
[27] Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
Wei, Guoqing
Ding, Lijuan
Wang, Jiasheng
Hu, Yongxian
Huang, He
EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2017, 6
[28] Potent Anti-leukemia Activities of Chimeric Antigen Receptor-Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia
Hu, Yongxian
Wu, Zhao
Luo, Yi
Shi, Jimin
Yu, Jian
Pu, Chengfei
Liang, Zuyu
Wei, Guoqing
Cui, Qu
Sun, Jie
Jiang, Jing
Xie, Jue
Tan, Yamin
Ni, Wanmao
Tu, Jifang
Wang, Jinping
Jin, Aiyun
Zhang, Hao
Cai, Zhen
Xiao, Lei
Huang, He
CLINICAL CANCER RESEARCH, 2017, 23 (13) : 3297 - 3306
[29] Safety and efficacy of a humanized CD19 chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia
Shi, Ming
Li, Li
Wang, Shiyuan
Cheng, Hai
Chen, Wei
Sang, Wei
Qi, Kunming
Li, Zhenyu
Wang, Gang
Li, Huizhong
Lan, Jianping
Huang, Jinqi
Fei, Xiaoming
Yu, Min
Li, Fei
Qiao, Jianlin
Wu, Qingyun
Zeng, Lingyu
Jing, Guangjun
Zheng, Junnian
Gale, Robert Peter
Xu, Kailin
Cao, Jiang
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (06) : 711 - 718
[30] Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy
Iqbal, Madiha
Jagadeesh, Deepa
Chavez, Julio
Khurana, Arushi
Rosenthal, Allison
Craver, Emily
Epperla, Narendranath
Li, Zhuo
Isufi, Iris
Awan, Farrukh T.
Dholaria, Bhagirathbhai R.
Maakaron, Joseph E.
Sandoval-Sus, Jose D.
Mishra, Rahul
Saha, Aditi
Annunzio, Kaitlin
Bhaskar, Shakthi T.
Sumransub, Nuttavut
Fijalka, Andrew
Ivanov, Stanislav A.
Lin, Yi
Kharfan-Dabaja, Mohamed A.
BONE MARROW TRANSPLANTATION, 2024, 59 (02) : 211 - 216

← 1 2 3 4 5 →